Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Stock Short Interest Report for October

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 229,146 shares, an increase of 1,343.5% from the September 30th total of 15,874 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 954,798 shares, the short-interest ratio is currently 0.2 days.

Oncotelic Therapeutics Stock Down 3.6%

Shares of OTCMKTS:OTLC traded down $0.00 during trading on Monday, hitting $0.02. The company’s stock had a trading volume of 342,035 shares, compared to its average volume of 407,391. The company has a market capitalization of $7.44 million, a PE ratio of 0.03 and a beta of -0.18. Oncotelic Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08. The stock’s 50-day moving average price is $0.03 and its two-hundred day moving average price is $0.04.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and other serious diseases. The company’s research has centered on RNA-based medicines and treatments designed to target biological pathways involved in tumor growth, immune regulation and disease progression.

Its lead product candidate, OT-101, is an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2), a signaling protein associated with tumor development and immune suppression.